Page 41 - Pharma Sector

Someone duplicated cough syrup to defame India: QP Pharma on WHO's alert

The World Health Organisation has issued a 'WHO Medical Product Alert' after "Substandard (contaminated)" Guaifenesin Syrup TG Syrup was found in the Marshall Islands and Micronesia

Mankind Pharma IPO subscribed 8% so far on Day 1; GMP down 30% in 10 days

The Rs 4,326-crore public issue's price band is set in the range of Rs 1,026-1,080 per share. The issue will close on Thursday, April 27

India business to boost pharma, after US sales prove to be a mixed bag

Hospitals to recover from sluggish Q3; diagnostics growth rate at pre-Covid levels

Results preview: India business to put a spring in pharma's step

Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels

Indian drug regulation standards should be at par with world: NITI Aayog

The NITI Aayog has recommended that Indian standards of drug regulation should be on par with global standards as well as aligned with the International Council for Harmonisation guidelines while promoting ease of doing business. The apex public policy think tank of the central government also suggested creating a separate authority to regulate medical devices in the country which is currently being monitored by the Drugs Controller General of India (DCGI). The recommendations have been made during the ongoing inter ministerial consultation on the New Drugs, Medical Devices and Cosmetics Bill, 2023. The draft New Drugs, Medical Devices and Cosmetics Bill, 2023, which seeks to replace the existing Drugs and Cosmetics Act of 1940, was put up on public domain in July last year seeking feedback from stakeholders. It has been revised and sent for inter-ministerial consultation. On clinical trials, the NITI Aayog said the draft bill should reflect the intent of overcoming the hesitancy

Big pharma: Here's why India's drug industry needs a major overhaul

The latest drug recalls just add to a long line of scandals that have tainted the pharma sector of India

Inverse H&S in pharma index could revive a positive bias for short-term

Pharma shares like Aurobindo Pharma, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals may rise up to 14 per cent.

Morepen Labs zooms 18% on USFDA nod with NIL observations for HP facility

Earlier this month, the company had incorporated a wholly-owned subsidiary, Morepen RX.

Specialty scale-up, product mix: Sun's medicine cabinet piques brokerages

In the near term, higher R&D costs and a recent acquisition to weigh on earnings growth

Multiple triggers likely to help Zydus to continue with its outperformance

New launches in the US, market share gains and steady domestic growth are positives

Serum Institute tops profit charts among unlisted firms amid Covid war

Surge in demand for Covishield led to a huge spike in its revenues and profits

India working on single-window portal for drug regulation processes

System will bring together stakeholders like manufacturers, distributors, state-run agencies to ensure quality

Industries minister inaugurates Himachal Pavilion at Pharma Live Expo

The state government participated in the country's largest pharma expo to showcase the pharma ecosystem and invite potential medical devices players for investments

Analysts turn cautious on Cipla as US FDA action delays key US launches

Analysts believe that some of the recent observations from the US FDA are critical in nature and could lead to a potential Official Action Indicated (OAI) classification for the Indore plant

Chintan shivir on drugs to diagnose and treat issues of trust, quality

Proposals to be discussed at Hyderabad conclave include having a centralised drug registration system under CDSCO

Former Ranbaxy, DRL exec Rajeev Raghuvanshi appointed as new DCGI

Appointment comes at a time when India's pharma regulatory landscape is under the scanner

Have to keep R&D spends at 12% of revenue: Biocon's Kiran Mazumdar-Shaw

It's a high growth phase for us in Biocon Biologics: We crossed the Rs 1,500-crore mark in revenue for the first time this quarter. We will exit this year (FY23) at Rs 2,000-crore level

Torrent Pharmaceuticals forays into OTC segment with calcium supplement

Torrent Pharmaceuticals on Tuesday said it has forayed into the over-the-counter segment in the country with Shelcal 500, a calcium supplement brand. With its composition of 500mg Calcium and 250 IU of Vitamin D3, Shelcal 500 helps optimise calcium absorption, increases bone density, improves muscle strength and helps boost immunity. The calcium is sourced from natural ingredients like oyster shell, having good absorption/bioavailability in the body. "With Shelcal's entry into OTC, the brand is poised to become the largest calcium supplement brand in India," Torrent Pharmaceuticals Director Aman Mehta said in a statement. According to studies, 40.6 per cent of Indians are calcium-deficient, while 79 per cent are Vitamin D-deficient.

Aurobindo Pharma's consolidated net profit down 18.7% at Rs 491 Cr in Q3

Aurobindo Pharma Limited on Thursday said its consolidated net profit for the quarter ended January 31 was down by 18.7 per cent to Rs 491.2 crore against Rs 604.3 crore in Q3FY22. A press release from the drug maker said revenue from operations during the quarter under discussion was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal. Commenting on the company's performance, K Nithyananda Reddy, Vice-Chairman and Managing Director of the company said "We witnessed an improved momentum backed by recovery across our business verticals and our endeavor is to continuously innovate and differentiate." In line with the companys commitment to innovate, there is an increase in the investments in Biosimilars. The company aims to sustain the momentum with new launches, improved cost efficiencies and adherence to the highest standards of compliance, supported by strong execution, he further said. During the quarter, formulation revenue increase by 9.2

With focus on non-US geographies, Amneal Pharma eyes India market

The company is actively recruiting its field force, and aims to have 600-700 medical representatives by the end of 2023